Skip to content Skip to footer
Subscribe Now
Insights+: EMA Marketing Authorization of New Drugs in February 2023
INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in February 2023

Shots:The EMA approved 7 New Chemical Entity (NCE) and 5 Biologic Drugs in February 2023, leading to treatments for patients and advances in the healthcare industryIn February 2023, the major highlights drugs were Forxiga’s Approval for symptomatic chronic heart failure, Fintepla for adjunctive treatment of seizures associated with lennox-gastaut syndromePharmaShots has compiled…
March 23, 2023

Read more

PharmaShots Interview Frank Leebeek & Greta Mulder of Erasmus MC, Lutz Bonacker of CSL Behring Share Insight on Etranacogene Dezaparvovec for the Treatment of Hemophilia B
VIEWPOINTS

PharmaShots Interview: Frank Leebeek & Greta Mulder of Erasmus MC, Lutz Bonacker of CSL Behring Share Insight on Etranacogene Dezaparvovec for the Treatment of Hemophilia B

In an interview with PharmaShots, Frank Leebeek, MD, Ph.D., Hematology Department Head & Greta Mulders, Nurse Practitioner, Study Coordinator at the Erasmus Medical Center in Rotterdam, Lutz Bonacker, Senior Vice President, General Manager, Commercial Operations Europe at CSL Behring shared their views on the data of Etranacogene Dezaparvovec in P-III (HOPE-B) trial for the treatment of Hemophilia B, presented at EAHAD 2022…
April 4, 2022

Read more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]